Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity.
Galanin-like peptide (GALP) is a neuropeptide involved in the regulation of food intake behavior, body weight and energy metabolism. In previous studies, we demonstrated that the intranasal administration of GALP has weight loss effects, although the mechanism of this action was not clarified. The aim of this study was to demonstrate the functional significance of GALP on lipid metabolism in the liver. Mice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control). Body weights, along with lipid levels in the plasma and liver, and lipid metabolism-related gene expression in the liver were subsequently measured. Body weight gain was decreased by the GALP treatment compared to the control group. Lipid droplet levels in hepatocytes and hepatic triglyceride levels were decreased in the GALP group compared with the vehicle group, whereas hepatic fatty acid β-oxidation-related gene mRNA levels were increased in the GALP group. These results suggest that the intranasal administration of GALP has an inhibitory effect on lipid accumulation in the liver.
Department of Health and Nutrition, University of Human Arts and Sciences, Saitama, Japan.
Satoshi
S
Hirako
Department of Internal Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuhiro
N
Wada
Faculty of Health Care, Kiryu University, Gunma, Japan.
Haruaki
H
Kageyama
Department of Exercise and Sports Physiology, Hoshi University School of Pharmacy and Pharmaceutical Science, Japan.
Fumiko
F
Takenoya
Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan.
Hyounju
H
Kim
Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan.
Yuzuru
Y
Iizuka
Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan.
Akiyo
A
Matsumoto
Tokyo Shokuryo Dietitian Academy, Tokyo, Japan.
Mai
M
Okabe
Hoshi University School of Pharmacy and Pharmaceutical Sciences Global Research Center for Innovative Life Science, Peptide Drug Innovation, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.
Seiji
S
Shioda
D000281:Administration, Intranasal; D000818:Animals; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D059305:Diet, High-Fat / Q000009:adverse effects*; D044089:Galanin-Like Peptide / Q000008:administration & dosage*; D050356:Lipid Metabolism / Q000187:drug effects* / Q000502:physiology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D016896:Treatment Outcome
D044089:Galanin-Like Peptide
DIO; GALP; fatty liver; high fat diet; lipid metabolism; triglycerides